StockNASDAQ · US · USDHealthcare · Medical Devices
$BRKR
BRUKER CORP
Bruker develops, manufactures and distributes scientific instruments and analytical and diagnostic solutions for customers in life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics and nanotechnology. Its products help users detect, measure and visualize samples at microscopic, molecular and cellular levels. Bruker is headquartered in Billerica, Massachusetts, and maintains technical and manufacturing centers in Europe and North America, with sales offices worldwide. Bruker operates four reportable segments: BSI BioSpin, BSI CALID, BSI NANO and Bruker Energy & Supercon Technologies. Its offerings include magnetic resonance, mass spectrometry, chromatography, X-ray, microscopy, metrology and molecular spectroscopy instruments, as well as diagnostic tests, software, automation and lifecycle services. Customers include academic and government research facilities, pharmaceutical and biotechnology companies, hospitals, industrial businesses and clinical laboratories. Bruker makes money by selling instruments, diagnostic products and related software and services.
Bruker Corp. (BRKR) appointed Eicke Latz to its Board of Directors, effective January 1, 2027. Latz will serve until the 2029 Annual Meeting of Stockholders, with committee assignments and compensation to be determined.
BRUKER CORP (BRKR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Professor Eicke Latz has co-founded five biotechnology companies, including IFM Therapeutics, Odyssey Therapeutics, Metaimmune Therapeutics, DiosCure Therapeutics, and Beren Therapeutics. His entrepreneurial efforts have focused on translating cutting-edge discoveries in innate i
Bruker Corp. (BRKR) reorganized its reportable segments effective July 1, 2026, and provided recast historical financial information. The four new segments are BSI BIOS, BMID, BSI NANO, and BEST. The realignment did not affect historical consolidated results, financial position, or cash flows. Bruker supplied recast segment data for 2024–2026 reporting periods to align with the new structure.
via TradingView
BRKR sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning BRKR (BRUKER CORP). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent BRKR coverage spans financial news, corporate actions and earnings.
What's driving BRKR
Board appointment is a routine governance change with limited immediate market impact.
AlphAI scores every news story that mentions BRKR with an AI model for sentiment and relevance, and aggregates insider trades from BRUKER CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Bruker Corp. (BRKR) appointed Eicke Latz to its Board of Directors, effective January 1, 2027. Latz will serve until the 2029 Annual Meeting of Stockholders, with committee assignments and compensation to be determined.
BRUKER CORP (BRKR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Professor Eicke Latz has co-founded five biotechnology companies, including IFM Therapeutics, Odyssey Therapeutics, Metaimmune Therapeutics, DiosCure Therapeutics, and Beren Therapeutics. His entrepreneurial efforts have focused on translating cutting-edge discoveries in innate i
Bruker Corp. (BRKR) reorganized its reportable segments effective July 1, 2026, and provided recast historical financial information. The four new segments are BSI BIOS, BMID, BSI NANO, and BEST. The realignment did not affect historical consolidated results, financial position, or cash flows. Bruker supplied recast segment data for 2024–2026 reporting periods to align with the new structure.
BRUKER CORP (BRKR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 As Reported As Recast Bruker Scientific Instruments ("BSI") BioSpin BSI Chemicals, Applied Markets, Life Sciences, In Vitro Diagnostics, Detection ("BSI CALID") BSI NANO Bruker Energy & Supercon Technologies ("BEST") Corporate Total BSI Biosystems ("BIOS") BSI Microb
Bruker Corp. (BRKR) reported a Q3 loss of $111.8M, or 81 cents per share, but adjusted earnings of 56 cents per share, exceeding analyst expectations of 42 cents. Revenue was $874M. The company forecasts full-year earnings of $2.10-$2.15 per share and revenue of $3.52B-$3.56B. BRKR shares are up 20% YTD and 46% over the past year.
BRUKER CORP (BRKR) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share, of $3.9844 per share. The dividend was declared on October 29, 2026, and is
Bruker Corporation's stock rose 6.3% to $59.45 on Wednesday, part of a broader sector-wide rally. Peers TXG, 1521.HK, ADPT, and AVTR also saw gains of 3.7% to 13.3%. The move was driven by sector rotation and institutional interest, with no company-specific news. Bruker's trading volume reached 597,428 shares, adding value to its $9.1 billion market cap.
JPMorgan downgraded Bruker to 'Neutral' from 'Overweight' and set a price target of $60. The company's stock has seen a 5-day change of 56.19 USD, a 1st Jan change of -0.11%, and a 19.27% increase over a longer period.
Bruker (BRKR) announced new mass spectrometry workflows and a $6M NMR order from UC Berkeley. Analysts expect 5.0% annual revenue growth and margin expansion to 13.4% by 2029, with earnings turning positive. However, execution risks and debt concerns remain. Current P/E is distorted by losses, trading lower than the life sciences peer group.
Analysts updated recommendations: Flutter (FLUT.L) downgraded to neutral with target cut to $119; Constellation Brands (STZ) kept underperform with target lowered to $110; eBay (EBAY) maintained underperform with target reduced to $75; Meta (META) kept overweight with target raised to $796. Other companies also received updates.